Table 4.

Adverse events associated with artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) treatment in Owando health facilities

Adverse events	ASAQ (n/N; %)				AL (n/N; %)a
	Day 1	Day 2	Day 3	Total	Day 1	Day 2	Total
Asthenia	4/61; 5.6	6/61; 9.8	3/59; 5.1	13/181; 7.2	1/57; 1.8	1/56; 1.8	2/113; 1.8
Vomiting	3/61; 4.9	0/61; 0	0/59; 0	3/181; 1.6	1/57; 1.8	0/56; 0	1/113; 0.9
Headache	0/61; 0	1/61; 1.6	0/59; 0	1/181; 0.6	0/57; 0	0/56; 0	0/113; 0
Urticaria	0/61; 0	1/61; 1.6	0/59; 0	1/181; 0.6	0/57; 0	0/56; 0	0/113; 0
Abdominal pain	1/61; 1.6	1/61; 1.6	1/59; 1.7	3/181; 1.7	0/57; 0	0/56; 0	0/113; 0
Total	8/61; 13.1	9/61; 14.8	4/59; 6.8	21/181; 11.6†	2/57; 0.7	1/56; 0.4	3/113: 2.7†

N number of patients followed up, n number of patients with adverse events

^aThere were no reported adverse events on day 3 in the AL group

^†There was a statistically significant difference (p = 0.004) in the proportions of ASAQ- and AL-treated patients reporting adverse events